Drug intelligence / Profile preview

AT-193

Development stage: Phase 1
Lead developer: Azora Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

AT-193 is a topical investigational small molecule drug developed by Azora Therapeutics for the treatment of dermatological conditions, primarily hidradenitis suppurativa. It acts as an agonist of the aryl hydrocarbon receptor (AHR), a nuclear receptor involved in skin barrier function and immune regulation. AHR agonists have shown efficacy in other inflammatory diseases, but AT-193 represents one of the first clinical studies targeting this pathway in hidradenitis suppurativa. The drug is administered topically and is currently in Phase 1 clinical trials for hidradenitis suppurativa, with additional development for plaque psoriasis, psoriatic arthritis, atopic dermatitis, and rare dermatological disorders[1][2][3][5][6].

Other names: AT193AT-193AT 193

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on AT-193.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-193.

Explore the full profile